Please login to the form below

Not currently logged in
Email:
Password:

Silence Therapeutics appoints Dr Annalisa Jenkins as non-executive chair

The Dimension Therapeutics CEO succeeds Dr Stephen Parker, who becomes a non-executive director

Annalisa JenkinsRNA-focused group Silence Therapeutics has appointed Dimension Therapeutics chief executive officer Dr Annalisa Jenkins as the non-executive chair of its board of directors.

She succeeds Dr Stephen Parker, the company’s non-executive chairman since September 2015, who becomes a non-executive director.

She said: “Silence's technology and IP represent a significant opportunity in the next generation of drugs that will potentially transform the treatment of serious diseases with significant unmet medical need, specifically where the liver is the primary target organ.

“These disorders often have devastating outcomes for patients and their families, and I look forward to contributing to the company’s advancement of these promising product candidates towards the clinic.”

Dr Jenkins brings over 25 years of global industry experience to Silence’s board, with expertise in scientific research, clinical development, regulatory approval and healthcare systems.

Prior to Dimension, Dr Jenkins held multiple leadership positions, including executive vice president, head of global research and development for Merck Serono and senior vice president, head of global medical affairs for Bristol Myers Squibb.

Ali Mortazavi, chief executive officer, Silence Therapeutics, said: “Annalisa’s extensive and broad experience in all aspects of biotechnology, drug development and commercialisation will prove to be invaluable.

“It is a testament to the progress made at Silence that we have been able to attract Annalisa to our Board.”

Dr Jenkins is also a committee member of the science board to the US Food and Drug Administration (FDA) and serves on the advisory board of its Center for Talent Innovation (UK).

25th October 2017

From: Sales

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Hayward Medical Communications

Hayward Medical Communications has been supporting partners in every sector of the healthcare industry to deliver evidence-based, clinically relevant and...

Latest intelligence

Precision paediatrics: Treating patients with CAR-T
Dr Stuart Adams specialises in using T-cell therapy to treat paediatric patients at Great Ormond Street Hospital. Here, he explains what it was like to develop and deliver a groundbreaking...
What does it mean to be an agile organisation
We spoke with Philip Atkinson to learn how healthcare and pharmaceutical companies can rapidly respond to changes in the market....
Battling breast cancer with precision medicine (Part 2)
Dr Mark Moasser treated breast cancer survivor Laura Holmes-Haddad (interviewed in part one) with an innovative precision medicine, which at the time was yet to be approved. Here he gives...

Infographics